Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Return on Sales (2016 - 2025)

Historic Return on Sales for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to 93.82%.

  • Cardiff Oncology's Return on Sales fell 219400.0% to 93.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 100.65%, marking a year-over-year decrease of 383400.0%. This contributed to the annual value of 66.46% for FY2024, which is 182600.0% up from last year.
  • Latest data reveals that Cardiff Oncology reported Return on Sales of 93.82% as of Q3 2025, which was down 219400.0% from 115.22% recorded in Q2 2025.
  • Cardiff Oncology's 5-year Return on Sales high stood at 48.81% for Q1 2024, and its period low was 149.65% during Q1 2022.
  • Over the past 5 years, Cardiff Oncology's median Return on Sales value was 81.37% (recorded in 2021), while the average stood at 91.84%.
  • Its Return on Sales has fluctuated over the past 5 years, first skyrocketed by 963900bps in 2024, then tumbled by -745000bps in 2025.
  • Over the past 5 years, Cardiff Oncology's Return on Sales (Quarter) stood at 71.62% in 2021, then dropped by -2bps to 73.38% in 2022, then grew by 19bps to 59.77% in 2023, then tumbled by -31bps to 78.05% in 2024, then fell by -20bps to 93.82% in 2025.
  • Its Return on Sales stands at 93.82% for Q3 2025, versus 115.22% for Q2 2025 and 123.31% for Q1 2025.